Rosetta Omics combines advanced molecular analysis and AI to help clinicians choose the cancer treatment most likely to work, and accelerate therapeutic discovery.
Every year, over 20 million people are diagnosed with cancer. Standard first-line therapies often fail, delaying effective care and driving up cost.
People diagnosed with cancer every year, worldwide.
Of patients do not fully respond to their first-line therapy.
Single tissue slide is all our platform needs to map a tumor.
See where disease happens inside the tissue.
Read the proteins driving each tumor.
Reveal how the tumor behaves at the RNA level.
Fuse every layer into clear clinical insight.
Four ways Rosetta Omics turns a routine biopsy into decisions oncologists can act on.
Improve diagnostic confidence through comprehensive molecular profiling of a single slide.
Identify which patients are most likely to benefit from specific therapies.
Support first-line treatment decisions with data-driven, patient-specific insights.
Accelerate biomarker discovery and novel target identification for biopharma partners.
Follow a patient's slide through the Rosetta Omics workflow: each step reveals itself as you scroll.
Scroll down to reveal the story
A single routine tissue slide, the same one oncologists already collect, becomes the starting point for a complete molecular story.
Our platform layers spatial biology, lipidomics, proteomics and gene expression on that slide, then fuses everything with AI into one coherent tumor map.
Oncologists get ranked, explainable insights: what the tumor is doing, which biomarkers matter, and which therapies are most likely to work.
The right treatment reaches the right patient sooner: improving outcomes and accelerating therapeutic discovery for biopharma partners.
Our CEO & Founder Dr. Wahid Awad presents Rosetta Omics: why the company was created, and how AI and spatial multiomics turn a single patient biopsy into insights that guide precision medicine. He also speaks candidly about the realities of building a deeptech company in health: the difficulty of accessing health data, the strict requirements that come with it, and how hard funding remains for deeptech startups.
Watch this video where our CEO Dr. Wahid Awad is featured by L'Œil de la Santé on the occasion of the ESANTE Summit, sharing the Rosetta Omics vision for AI-enabled precision oncology.
Watch this video where our CEO Dr. Wahid Awad receives the Grand Prix Startup Santé 2026, awarded by BFM Business, in recognition of Rosetta Omics' contribution to AI-enabled precision oncology.
Discover how Deeptech is transforming medicine. In this episode on Europe 1, our CEO Dr. Wahid Awad shares his vision of life-saving innovations in oncology.
COMING SOON EVENTRosetta Omics is joining the Pfizer Healthcare Hub France Demo Night on October 1, 2026. After months in the 5th PHHF acceleration program, our CEO will present how spatial multi-omics and AI guide precision cancer care, and celebrate the journey alongside fellow health innovators, clinicians and investors.
Register
EVENTOur CEO & Founder Dr. Wahid Awad took part in the Universités Pharmaceutiques 2026 in Paris, speaking in the session "La 'vraie vie' des entrepreneurs". The round table offered a candid look at the realities of building a healthtech company: day-to-day challenges, regulatory complexity and strategic trade-offs, but also the resilience and conviction that drive healthcare innovation forward.
Read More
AWARD🚀 Breaking News: Rosetta Omics has been awarded the Grand Prix Startup Santé 2026 by BFM Business 🏆. A recognition of our team, partners, investors and ecosystem, and of our mission: unlocking the full potential of precision medicine in oncology to better predict treatment response and improve outcomes for patients.
Read MoreWhether you're an oncologist, a research partner, a drug developer, or a biopharma team, we'd love to talk about what precision medicine can look like for you.